TAP-inhibiting proteins US6, ICP47 and UL49.5 differentially affect minor and major histocompatibility antigen-specific recognition by cytotoxic T lymphocytes
1 Department of Immunohematology and Blood Transfusion and
2 Department of Medical Microbiology, Leiden University Medical Center, Albinusdreef 2, 2300RC Leiden, The Netherlands
3 Present address: Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
Correspondence to: L. E. M. Oosten; E-mail: l.e.m.oosten{at}lumc.nl
CTLs specific for hematopoietic system-restricted minor histocompatibility antigens (mHags) can serve as reagents for cellular adoptive immunotherapy after allogeneic stem cell transplantation (SCT). In the HLA-mismatched setting, CTLs specific for hematopoietic system-restricted mHags expressed solely by the non-self ‘allo’ HLA molecules could be used to treat relapse after HLA-mismatched SCT. The generation of mHag-specific allo-HLA-restricted CTLs requires antigen-presenting cells (APCs) expressing low numbers of endogenous peptides to avoid co-induction of undesired allo-HLA reactivities. In this study, we exploited viral evasion strategies to generate APCs expressing a controlled set of endogenous peptides. Herpesviruses persist lifelong following primary infection due to expression of viral gene products that hamper T-cell recognition of infected cells. The herpesvirus-derived proteins US6, ICP47 and UL49.5 down-regulate endogenous antigen presentation in human APCs via inhibition of the transporter associated with antigen processing. EBV-transformed B cell lines transduced with retroviral vectors encoding US6, ICP47 or UL49.5 exhibited a stable decrease in cell-surface HLA class I expression and were protected from lysis by mHag-specific CTLs. Exogenous addition of mHag peptide fully restored target cell recognition. UL49.5 showed the most pronounced inhibitory effect, reducing HLA class I expression and mHag-specific lysis up to 99%. UL49.5 also significantly diminished allo-HLA reactivities mediated by allo-HLA-specific CTLs. In conclusion, UL49.5 could be a powerful new tool to study and modulate endogenous antigen presentation.
Keywords: antigen presentation/processing, cytotoxicity, recombinant viral vectors
* These authors contributed equally to this study.
Transmitting editor: G. J. Hammerling
This article has been corrected to remove the word ‘hemagglutinin’ from between the words "(mHags)" and "HA-1 or HA-2" in the first sentence of the introduction. The following equation in the last paragraph of the ‘Flow cytometric analyses’ paragraph has been corrected to read: MFI = [mean fluorescence sample 1 - mean fluorescence of secondary control] + [mean fluorescence sample 2 - mean fluorescence of secondary control]/2
Received 16 November 2006, accepted 21 June 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Horst, D. van Leeuwen, N. P. Croft, M. A. Garstka, A. D. Hislop, E. Kremmer, A. B. Rickinson, E. J. H. J. Wiertz, and M. E. Ressing Specific Targeting of the EBV Lytic Phase Protein BNLF2a to the Transporter Associated with Antigen Processing Results in Impairment of HLA Class I-Restricted Antigen Presentation J. Immunol., February 15, 2009; 182(4): 2313 - 2324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Verweij, D. Koppers-Lalic, S. Loch, F. Klauschies, H. de la Salle, E. Quinten, P. J. Lehner, A. Mulder, M. R. Knittler, R. Tampe, et al. The Varicellovirus UL49.5 Protein Blocks the Transporter Associated with Antigen Processing (TAP) by Inhibiting Essential Conformational Transitions in the 6+6 Transmembrane TAP Core Complex J. Immunol., October 1, 2008; 181(7): 4894 - 4907. [Abstract] [Full Text] [PDF]
|
|